Immune characterization of thyroid neoplasm's and its variants using immunohistochemical markers: CK-19, Galectin-3 and Hector Battifora mesothelial-1

Nehal, Shamaila; Mittal, Ruchi; Misra, Pranati; Rath, Jayasree; Senapati, Urmila

doi:10.1016/j.anndiagpath.2022.151931

Cited by 1 publication

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, in a study on 18 cases of atypical follicular thyroid nodules characterized by a solid growth pattern, 17/18 cases were negative for CK-19 [30]. Consistent with this fnding, Nehal et al [31] have demonstrated that, in a series of thyroid lesions, CK-19 was expressed in all the papillary thyroid carcinoma specimens, as well as in 87.5% of adenomatous hyperplasia, whereas it was absent in follicular adenomas and follicular carcinomas.…”

Section: Discussionmentioning

confidence: 68%

“…CK-19 is a low molecular weight cytokeratin found in basal layers of stratified epithelium and simple epithelia, which is upregulated in neoplastic transformation. It has been shown that papillary thyroid carcinomas exhibit an intense diffuse expression of CK-19, whereas follicular carcinomas show a heterogeneous expression of CK-19, which tends to be absent in follicular adenomas [ 20 , 30 , 31 ]. Likewise, in a study on 18 cases of atypical follicular thyroid nodules characterized by a solid growth pattern, 17/18 cases were negative for CK-19 [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunocytochemistry Profile of Benign Thyroid Nodules Not Responding to Thermal Ablation: A Retrospective Study

Bernardi

Taccogna

D’Angelo

et al. 2023

International Journal of Endocrinology

View full text Add to dashboard Cite

Purpose. Thermal ablations (TA) are gaining ground as alternative options to conventional therapies for symptomatic benign thyroid nodules. Little is known about the impact of nodule biology on the outcomes of TA. The aim of our study was to evaluate the baseline immunocytochemistry profile of thyroid nodules that were poorly responsive to TA in order to identify potential predictors of the treatment response. Methods. From a cohort of 406 patients with benign thyroid nodules treated with TA and followed for 5 years, we retrospectively selected two groups of patients: NONRESPONDERS (patients who did not respond to TA and were later surgically treated) and RESPONDERS (patients who responded to TA). The fine-needle aspiration cytology (FNAC) slides obtained before TA were stained for Galectin-3, HBME-1, CK-19, and Ki-67. Results. Benign nodules of NONRESPONDERS (n = 19) did not express CK-19 ( p = 0.03 ), as compared to RESPONDERS (n = 26). We combined the absence of CK-19 and the presence of Ki-67 to obtain a composite biomarker of resistance to TA, which discriminated between likelihood of retreatment and no retreatment with an AUC of 0.68 (95%CI: 0.55-0.81) and a sensitivity, specificity, PPV, and NPV of 29%, 91%, 71%, and 64%, respectively. Conclusion. In benign thyroid nodules, the absence of CK-19 was associated with resistance to TA, while the presence of CK-19 was predictive of response to TA. If confirmed, this finding could provide rapid and inexpensive information about the potential outcome of TA on benign thyroid nodules. In addition, as CK-19 can be expressed in adenomatous hyperplasia, it could be speculated that these nodules, rather than follicular adenomas, might be better candidates for TA.

show abstract

Section: Discussionmentioning

confidence: 68%